Amicus Therapeutics, Inc. (FOLD)
After hours:
Chart Events
Performance Outlook
| Previous Close | 10.91 |
| Open | 11.03 |
| Bid | 10.73 x 800 |
| Ask | 11.10 x 1300 |
| Day's Range | 11.00 - 11.21 |
| 52 Week Range | 5.91 - 13.84 |
| Volume | |
| Avg. Volume | 2,233,033 |
| Market Cap | 3.135B |
| Beta (5Y Monthly) | 0.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.83 |
| Earnings Date | May 08, 2023 - May 12, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.82 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for FOLD
Related Research
- Amicus Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 05/28/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 years agoArgus Research
- Zacks
Amicus Therapeutics (FOLD) Down 14% Since Last Earnings Report: Can It Rebound?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease CHMP Opinion for Miglustat, the Oral Enzyme Stabilizer Component of AT-GAA, On-Track for 2Q 2023 PHILADELPHIA, March 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the European Commission (EC) has grant
- Insider Monkey
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2022 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics Full Year 2022 financial results conference call and webcast. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at […]
